Comparison of efficacy and safety between tildrakizumab and secukinumab in the treatment of moderate-to-severe plaque psoriasis
- VernacularTitle:替瑞奇珠单抗与司库奇尤单抗治疗中重度斑块状银屑病的疗效和安全性对比
- Author:
Ning CHEN
1
;
Yaoju FENG
2
;
Yu DING
1
Author Information
1. Dept. of Dermatology，the First Affiliated Hospital of Nanyang Medical College，Henan Nanyang 473000，China
2. Dept. of Rheumatology，the First Affiliated Hospital of Nanyang Medical College，Henan Nanyang 473000，China
- Publication Type:Journal Article
- Keywords:
tildrakizumab;
secukinumab;
moderate-to-severe plaque psoriasis;
efficacy;
safety;
biological agent
- From:
China Pharmacy
2026;37(7):933-937
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To compare the efficacy and safety of tildrakizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis. METHODS A retrospective analysis was conducted on 141 patients with moderate-to-severe plaque psoriasis treated at the First Affiliated Hospital of Nanyang Medical College from January 2024 to April 2025. According to the treatment regimen，the patients were divided into tildrakizumab g roup （ n ＝61） and secukinumab group （ n ＝80）. The PASI 75，PASI 90，and PASI 100 response rates， the Psoriasis Area and Severity Index （PASI） and Dermatology Life Quality Index （DLQI） scores， skin barrier function （sebum content and stratum corneum water content）， inflammatory factor levels [interleukin-17 （IL-17）， tumor necrosis factor-α （TNF-α）， and IL-23 ] before and after treatment， and the incidence of adverse drug reactions during treatment were compared between the two groups. RESULTS After 12 weeks of treatment， the PASI 75， PASI 90， and PASI 100 response rates in the tildrakizumab group were significantly higher than those in the secukinumab group （ P ＜0.05）. After treatment， PASI and DLQI scores as well as serum levels of IL-17， TNF-α， and IL-23 in both groups were significantly reduced compared to before treatment in the same group； sebum content and stratum corneum water content were significantly increased compared to before treatment in the same group （ P ＜0.05）； the tildrakizumab group showed better results than the secukinumab group （ P ＜0.05）. The overall incidence of adverse drug reactions was also significantly lower in the tildrakizumab group compared with the secukinumab group （ P ＜0.05）. CONCLUSIONS Compared with secukinumab， tildrakizumab demonstrates superior efficacy in the treatment of moderate-to-severe plaque psoriasis， providing improved symptom relief， enhanced skin barrier function， reduced levels of inflammatory factors， and higher safety.
